Skip to main content

Advertisement

SpringerLink
Log in

Complications of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Advanced Ovarian Malignancies: First Indian Study

  • Published:
Indian Journal of Gynecologic Oncology Aims and scope Submit manuscript

Abstract

Background

Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) has been proposed as a treatment for advanced ovarian carcinoma and pseudomyxoma peritonii. We analyzed the perioperative complications of extensive CRS + HIPEC in Indian patients with advanced ovarian malignancies and pseudomyxoma peritonii.

Methods

In this prospective observational study, we included 38 patients from February 2013 to June 2015 with advanced EOC and pseudomyxoma peritonii treated by a dedicated peritoneal malignant disease treatment team in a tertiary care hospital. All patients underwent extensive CRS + HIPEC. The post-operative morbidity and mortality were analyzed.

Results

Our patients were grouped into frontline 21.1 % (n = 8), interval cytoreduction 50 % (n = 19), and secondary cytoreduction 28.9 % (n = 11) based on the timeline at presentation. Mean peritoneal carcinomatosis index (PCI) was 8.5 ± 7.45 (range 3–36). Average surgery duration was 9 ± 2.7 h (range 5.5–19). Mean perfusion temperature used was (42 ± 0.49 °C). Patients with PCI score ≥15 had prolonged gastrointestinal recovery (p = 0.043), post-operative ventilator need (p = 0.011), acute respiratory distress syndrome (ARDS) (p = 0.014), and dyspnea (p = 0.002) with trend towards adverse events. Closed method HIPEC was associated with prolonged hospital stay (p = 0.011), wound-related complications (p = 0.006), and ARDS (p < 0.001). Multivisceral resections were associated with increased ventilator need (p < 0.001), ARDS (p = 0.010), and adverse events (p = 0.044). The recurrent ovarian carcinomas were associated with more wound-related complications (p = 0.016). More adverse events with cisplatin 100 mg/m2 (p = 0.03) were dyselectrolytemia, acute renal failure, and fall in hemoglobin. No 30-day mortality was present. After a median follow-up of 17 (3–28) months, 15.8 % patients (n = 6) had recurrences and 5.3 % (n = 2) succumbed to disease.

Conclusion

Ovarian peritoneal malignancies known for peritoneal recurrences are amenable for extensive cytoreduction and HIPEC with acceptable morbidity in Indian patients. A dedicated team of surgeon, anesthetist, medical oncologist, and intensivist is mandatory for better outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Dhillon PK, Yeole BB, Dikshit R, Kurkure AP, Bray F. Trends in breast, ovarian and cervical cancer incidence in Mumbai, India over a 30-year period, 1976–2005: an age–period–cohort analysis. Br J Cancer. 2011;105:723–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–59.

    Article  PubMed  Google Scholar 

  3. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2009;112:265–74.

    Article  PubMed  Google Scholar 

  4. Esquivel J, Sugarbaker PH. Elective surgery in recurrent colon cancer with peritoneal seeding: when to and when not to proceed. Cancer Ther. 1998;1:321–5.

    Google Scholar 

  5. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950–5.

    Article  CAS  PubMed  Google Scholar 

  6. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001–7.

    CAS  PubMed  Google Scholar 

  7. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43.

    Article  CAS  PubMed  Google Scholar 

  8. Van der Speeten K, Stuart OA, Sugarbaker PH. Pharmacokinetics and pharmacodynamics of perioperative cancer chemotherapy in peritoneal surface malignancy. Cancer J. 2009;15:216–24.

    Article  PubMed  Google Scholar 

  9. Smeenk RM, Verwaal VJ, Zoetmulder FA. Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg. 2007;94(11):1408–14.

    Article  CAS  PubMed  Google Scholar 

  10. Deraco M, Kusamura S, Virzì S, Puccio F, Macrì A, Famulari C, Solazzo M, Bonomi S, Iusco DR, Baratti D. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. Gynecol Oncol. 2011;122(2):215–20.

    Article  PubMed  Google Scholar 

  11. Halkia E, Kopanakis N, Nikolaou G, Spiliotis J. Cytoreductive surgery and HIPEC for peritoneal carcinomatosis: a review on morbidity and mortality. J BUON. 2015;20(Suppl. 1):S80–7.

    PubMed  Google Scholar 

  12. Deraco M, Virzì S, Iusco DR, Puccio F, Macrì A, Famulari C, Solazzo M, Bonomi S, Grassi A, Baratti D, Kusamura S. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study. BJOG. 2012;119(7):800–9.

    Article  CAS  PubMed  Google Scholar 

  13. Elias D, Antoun S, Goharin A, et al. Research on the best chemohyperthermia technique of treatment of peritoneal carcinomatosis after complete resection. Int J Surg Investig. 2000;1:431–9.

    CAS  PubMed  Google Scholar 

  14. Yan TD, Links M, Fransi S, Jacques T, Black D, Saunders V, Morris DL. Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy—a journey to becoming a Nationally Funded Peritonectomy Center. Ann Surg Oncol. 2007;14(8):2270–80.

    Article  PubMed  Google Scholar 

  15. Chan DL, Morris DL, Rao A, Chua TC. Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy. Cancer Manag Res. 2012;4:413–22.

    PubMed  PubMed Central  Google Scholar 

  16. Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 2011;11:CD005340.

  17. Fagotti A, Costantini B, Petrillo M, et al. Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up. Gynecol Oncol. 2012;127:502–5.

    Article  PubMed  Google Scholar 

  18. Bakrin N, Cotte E, Golfier F, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients. Ann Surg Oncol. 2012;19:4052–8.

    Article  CAS  PubMed  Google Scholar 

  19. Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, Giassas S. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22(5):1570–5.

    Article  CAS  PubMed  Google Scholar 

  20. Fagotti A, et al. HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome. Gynecol Oncol. 2011;122(2):221–5. doi:10.1016/j.ygyno.2011.04.008.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Manipal Comprehensive Cancer Center, Manipal Hospital, 98, HAL Airport Road, Bengaluru, 560017, India

    Somashekhar SP, Prasanna G & Rajshekhar Jaka

  2. Department of Medical Oncology, Manipal Comprehensive Cancer Center, Manipal Hospital, Bengaluru, India

    Amit Rauthan

  3. Department of Anesthesiology, Manipal Hospital, Bengaluru, India

    Murthy HS

  4. Department of Critical Care, Manipal Hospital, Bengaluru, India

    Sunil Karanth

Authors
  1. Somashekhar SP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prasanna G
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rajshekhar Jaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Amit Rauthan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Murthy HS
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sunil Karanth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Prasanna G.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

SP, S., G, P., Jaka, R. et al. Complications of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Advanced Ovarian Malignancies: First Indian Study. Indian J Gynecol Oncolog 13, 8 (2015). https://doi.org/10.1007/s40944-015-0011-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s40944-015-0011-7

Keywords

Search

Navigation